Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma von Eturi, Aditya, Bhasin, Amman, Zarrabi, Kevin K, Tester, William J

Volltext

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer von Palecki, Julia, Bhasin, Amman, Bernstein, Andrew, Mille, Patrick J., Tester, William J., Kelly, Wm. Kevin, Zarrabi, Kevin K.

Volltext

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer von Zarrabi, Kevin K., Narayan, Vivek, Mille, Patrick J., Zibelman, Matthew R., Miron, Benjamin, Bashir, Babar, Kelly, William Kevin

Volltext

Association of Acute Rejection and De Novo Renal Cell Carcinoma in Kidney Transplant Patients: An OPTN Data Analysis von Casey, Molly E., Yanacek, Emmalie, Kaul, Hitesh, Knorr, John P., Khanmoradi, Kamran, Parsikia, Afshin, Chandolias, Nikolaos, Zarrabi, Kevin K., Zaki, Radi

Volltext

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma von Zarrabi, Kevin K, Handorf, Elizabeth, Miron, Benjamin, Zibelman, Matthew R, Anari, Fern, Ghatalia, Pooja, Plimack, Elizabeth R, Geynisman, Daniel M

Volltext

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma von Zarrabi, Kevin K., Lanade, Oladimeji, Geynisman, Daniel M.

Volltext

Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma von Zarrabi, Kevin K., Vaishampayan, Ulka, Barata, Pedro C.

Volltext

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers von Barata, Pedro C., Zarrabi, Kevin K., Bex, Axel, Grivas, Petros, Hermann, Ken, Hofman, Michael S., Li, Roger, Lopez-Beltran, Antonio, Padani, Anwar R., Powles, Thomas, Taplin, Mary-Ellen, Loriot, Yohann

Volltext

Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses von Zarrabi, Kevin K, Miron, Benjamin, Geynisman, Daniel M

Volltext

Assessing plasma circulating tumor human papillomavirus (HPV) DNA in determining treatment response in HPV‐associated oropharyngeal cancer von Zarrabi, Kevin K., Galloway, Thomas J., Flieder, Douglas B., Kumar, Sameera S., Judd, Julia, Bauman, Jessica R.

Volltext

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer von Simão, Diana C, Zarrabi, Kevin K, Mendes, José L, Luz, Ricardo, Garcia, Jorge A, Kelly, William K, Barata, Pedro C

Volltext

Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma von Zarrabi, Kevin K, Saxena, Abhiraj, Mouw, Kent W, Koshkin, Vadim S, Friedlander, Terence

Volltext

Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC) von Mar, Nataliya, Dwabe, Sami, Baranda, Marlon N., Zarrabi, Kevin K., Eturi, Aditya, Gulati, Shuchi, Parikh, Mamta, Seyedin, Steven N., Kalebasty, Arash Rezazadeh

Volltext

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes von Zorko, Nicholas A, Makovec, Allison, Elliott, Andrew, Kellen, Samuel, Lozada, John R, Arafa, Ali T, Felices, Martin, Shackelford, Madison, Barata, Pedro, Zakharia, Yousef, Narayan, Vivek, Stein, Mark N, Zarrabi, Kevin K, Patniak, Akash, Bilen, Mehmet A, Radovich, Milan, Sledge, George, El-Deiry, Wafik S, Heath, Elisabeth I, Hoon, Dave S B, Nabhan, Chadi, Miller, Jeffrey S, Hwang, Justin H, Antonarakis, Emmanuel S

Volltext

Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau? von Hochberg, Aaron R, Gomella, Patrick T, Im, Brian, Ghosh, Anushka, Shah, Sohan, Thompson, Rasheed A M, Zarrabi, Kevin K, Shah, Mihir S, Mark, J Ryan, Izes, Joseph K, Lallas, Costas D, Gomella, Leonard G, Metwalli, Adam R

Volltext

Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized... von Jang, Albert, Zhong, Jeffrey Y., Kumar, Hamsa L.S., Zarrabi, Kevin K., Zhu, Alec, Grier, Abby L., Calaway, Adam, Shoag, Jonathan E., Bukavina, Laura, Jia, Angela Y., Mendiratta, Prateek, Sheng, Iris Y., Rao, Santosh, Brown, Jason R., Garcia, Jorge A., Margevicius, Seunghee, Fu, Pingfu, Barata, Pedro C.

Volltext

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma von Zarrabi, Kevin K, Lanade, Oladimeji, Geynisman, Daniel M

Volltext

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer von Simão, Diana C, Zarrabi, Kevin K, Mendes, José L, Luz, Ricardo, Garcia, Jorge A, Kelly, William K, Barata, Pedro C

Volltext

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma von Zarrabi, Kevin K, Handorf, Elizabeth, Miron, Benjamin, Zibelman, Matthew R, Anari, Fern, Ghatalia, Pooja, Plimack, Elizabeth R, Geynisman, Daniel M

Volltext

Assessing plasma circulating tumor human papillomavirus (HPV) DNA in determining treatment response in HPV-associated oropharyngeal cancer von Zarrabi, Kevin K, Galloway, Thomas J, Flieder, Douglas B, Kumar, Sameera S, Judd, Julia, Bauman, Jessica R

Volltext